Google
Apple
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
GILEAD SCIENCES, INC. | Delayed Nasdaq 04:00:00 2023-09-22 pm EDT |
|
5-day change | 1st Jan Change | |
| 75.01 USD | -0.35% | -0.87% | -12.63% | |
Financials (USD)
| Sales 2023 * | 26,872 M | Sales 2024 * | 27,519 M | Capitalization | 93 788 M |
|---|---|---|---|---|---|
| Net income 2023 * | 5,763 M | Net income 2024 * | 6,621 M | EV / Sales 2023 * | 4,01x |
| Net Debt 2023 * | 14,092 M | Net Debt 2024 * | 9,430 M | EV / Sales 2024 * | 3,75x |
| P/E ratio 2023 * | 16,3x | P/E ratio 2024 * | 13,9x | Employees | - |
| Yield 2023 * | 4,07% | Yield 2024 * | 4,25% | Free-Float | 99.89% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
More news
| 1 day | -0.73% | ||
| 1 week | -2.70% | ||
| Current month | -1.58% | ||
| 1 month | -0.88% | ||
| 3 months | -3.02% | ||
| 6 months | -4.89% | ||
| Current year | -12.32% |
1 week
75.14
76.39
1 month
73.2578.98
Current year
73.2588.29
1 year
61.4589.74
3 years
56.5689.74
5 years
56.5689.74
10 years
56.56123.37
| Managers | Title | Age | Since |
|---|---|---|---|
Daniel O'Day
CEO | Chief Executive Officer | 58 | 2019 |
Andrew Dickinson
DFI | Director of Finance/CFO | 53 | 2019 |
Flavius Martin
CTO | Chief Tech/Sci/R&D Officer | - | 2021 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Javier Rodriguez
BRD | Director/Board Member | 52 | 2020 |
Daniel O'Day
CHM | Chairman | 58 | 2019 |
Kevin Lofton
BRD | Director/Board Member | 68 | 2009 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 13.99% | 189 M$ | -6.70% | - | |
| 3.55% | 2 M$ | -0.04% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 23-09-22 | 75.01 | -0.35% | 4 351 809 |
| 23-09-21 | 75.27 | -0.73% | 5,272,598 |
| 23-09-20 | 75.82 | +0.07% | 4,826,589 |
| 23-09-19 | 75.77 | +0.20% | 4,002,720 |
| 23-09-18 | 75.62 | -0.07% | 3,337,942 |
Delayed Quote Nasdaq, September 21, 2023 at 04:00 pm EDT
More quotes
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows:
- sale of drugs (98.9%): for the treatment of HIV (50% of net sales), COVID-19 (7.4%), hepatitis C virus (4%), hepatitis B virus (1.4%) and other (37.2%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV);
- other (1.3%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products.
Net sales are distributed geographically as follows: the United States (70.6%), Europe (17.8%) and other (11.6%).
Sector
Pharmaceuticals
Calendar
2023-10-25
- Q3 2023 Earnings Release (Projected)
Trading Rating :
Investor Rating :
ESG Refinitiv :
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
29
Last Close Price
75.27USD
Average target price
91.36USD
Spread / Average Target
+21.38%
EPS Revisions
| 1st Jan change | Capi. (M$) | |
|---|---|---|
| -12.32% | 93 788 M $ | |
| +6.84% | 76 262 M $ | |
| -17.89% | 123 B $ | |
| +0.97% | 63 659 M $ | |
| -8.64% | 50 834 M $ | |
| +14.09% | 137 B $ | |
| +14.74% | 50 104 M $ | |
| -1.15% | 50 043 M $ | |
| +26.34% | 47 593 M $ | |
| +2.58% | 144 B $ |
